Bank of America Corporation reaffirmed their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a report published on Monday morning. They currently have a $135.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $117.00.
PBYI has been the subject of several other reports. J P Morgan Chase & Co reaffirmed a buy rating and issued a $131.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, October 4th. Leerink Swann reaffirmed an outperform rating and issued a $125.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, August 2nd. BidaskClub raised Puma Biotechnology from a buy rating to a strong-buy rating in a research note on Monday, July 31st. Royal Bank Of Canada set a $88.00 price objective on Puma Biotechnology and gave the company a hold rating in a research note on Monday, July 17th. Finally, Citigroup Inc. reaffirmed a buy rating and issued a $105.00 price objective on shares of Puma Biotechnology in a research note on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and an average target price of $124.89.
Puma Biotechnology (PBYI) opened at 124.05 on Monday. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $127.02. The stock’s market capitalization is $4.62 billion. The firm has a 50-day moving average price of $105.42 and a 200-day moving average price of $75.89.
Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.78). Equities research analysts predict that Puma Biotechnology will post ($8.69) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/12/bank-of-america-corporation-reaffirms-buy-rating-for-puma-biotechnology-inc-pbyi.html.
In other news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the sale, the insider now directly owns 4,170,623 shares in the company, valued at $395,083,116.79. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Richard Paul Bryce sold 1,998 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the completion of the sale, the senior vice president now owns 27,246 shares in the company, valued at $2,574,202.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,173 shares of company stock worth $4,738,189. Company insiders own 22.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of PBYI. Wells Fargo & Company MN raised its holdings in shares of Puma Biotechnology by 10.0% in the first quarter. Wells Fargo & Company MN now owns 24,151 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 2,201 shares during the period. Swiss National Bank raised its holdings in shares of Puma Biotechnology by 2.1% in the first quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock worth $2,036,000 after buying an additional 1,100 shares during the period. Parametric Portfolio Associates LLC purchased a new stake in shares of Puma Biotechnology in the first quarter worth approximately $257,000. American International Group Inc. raised its holdings in shares of Puma Biotechnology by 19.2% in the first quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock worth $630,000 after buying an additional 2,733 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. purchased a new stake in shares of Puma Biotechnology in the first quarter worth approximately $603,000. Hedge funds and other institutional investors own 80.98% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.